Endoscopic and surgical management of hereditary nonpolyposis colorectal cancer

Clinics in Colon and Rectal Surgery

Volumn 25, Issue 2, 2012, Pages 90-96

  Baucom, Rebeccah B ^a   Wise, Paul E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

colon cancer; colorectal cancer; hereditary cancer syndrome; hereditary nonpolyposis colorectal cancer; HNPCC; Lynch syndrome

Indexed keywords

EID: 84861640401     PISSN: 15310043     EISSN: 15309681     Source Type: Journal    
DOI: 10.1055/s-0032-1313779     Document Type: Article

References (39)

1. Kalady MF, McGannon E, Vogel JD, Manilich E, Fazio VW, Church JM. Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria. Ann Surg: 2010; 252 3 507 511, discussion 511-513
2. Kalady MF. Surgical management of hereditary nonpolyposis colorectal cancer. Adv Surg: 2011; 45 265 274
3. Vasen HF, Watson P, Mecklin JP., et al. New clinical criteria for hereditary nonpolyposis colorectal cancer proposed by the International Collaborative Group on HNPCC. Gastroenterology: 1999; 116 1453 1456 (Pubitemid 29258894)
4. Hampel H, Frankel WL, Martin E., et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol: 2008; 26 35 5783 5788
5. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med: 2003; 348 10 919 932 (Pubitemid 36298000)
6. Vasen HF, Abdirahman M, Brohet R., et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology: 2010; 138 7 2300 2306
7. Herráiz M, Muñoz-Navas M. Recognition and management of hereditary colorectal cancer syndromes. Rev Esp Enferm Dig: 2009; 101 2 125 132
8. Natarajan N, Watson P, Silva-Lopez E, Lynch HT. Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis Colon Rectum: 2010; 53 1 77 82
9. Rodríguez-Bigas MA, Vasen HF, Pekka-Mecklin J., et al. International Collaborative Group on HNPCC Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. Ann Surg: 1997; 225 2 202 207 (Pubitemid 27083780)
10. Järvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology: 1995; 108 5 1405 1411
11. Järvinen HJ, Aarnio M, Mustonen H., et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology: 2000; 118 5 829 834 (Pubitemid 30243745)
12. Grover S, Syngal S. Risk assessment, genetic testing, and management of Lynch syndrome. J Natl Compr Canc Netw: 2010; 8 1 98 105
13. Lynch PM. Prevention of colorectal cancer in high-risk populations: the increasing role for endoscopy and chemoprevention in FAP and HNPCC. Digestion: 2007; 76 1 68 76 (Pubitemid 47608861)
14. East JE, Suzuki N, Stavrinidis M, Guenther T, Thomas HJ, Saunders BP. Narrow band imaging for colonoscopic surveillance in hereditary non-polyposis colorectal cancer. Gut: 2008; 57 1 65 70
15. Lecomte T, Cellier C, Meatchi T., et al. Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome. Clin Gastroenterol Hepatol: 2005; 3 9 897 902 (Pubitemid 41219293)
16. Hurlstone DP, Karajeh M, Cross SS., et al. The role of high-magnification-chromoscopic colonoscopy in hereditary nonpolyposis colorectal cancer screening: a prospective "back-to-backo" endoscopic study. Am J Gastroenterol: 2005; 100 10 2167 2173
17. Vasen HF, Möslein G, Alonso A., et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet: 2007; 44 6 353 362 (Pubitemid 46953715)
18. Parry S, Win AK, Parry B., et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut: 2011; 60 7 950 957
19. Celentano V, Luglio G, Antonelli G, Tarquini R, Bucci L. Prophylactic surgery in Lynch syndrome. Tech Coloproctol: 2011; 15 2 129 134
20. de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P., et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut: 2003; 52 1752 1755 (Pubitemid 37510398)
21. Van Dalen R, Church J, McGannon E, Fay S, Burke C, Clark B. Patterns of surgery in patients belonging to Amsterdam-positive families. Dis Colon Rectum: 2003; 46 5 617 620 (Pubitemid 36576418)
22. Olschwang S, Laurent-Puig P, Eisinger F, Millat B. An alternative to prophylactic colectomy for colon cancer prevention in HNPCC syndrome. Gut: 2005; 54 1 169 (Pubitemid 40007238)
23. Bleiker EM, Menko FH, Taal BG., et al. Screening behavior of individuals at high risk for colorectal cancer. Gastroenterology: 2005; 128 2 280 287 (Pubitemid 40431081)
24. Lee JS, Petrelli NJ, Rodriguez-Bigas MA. Rectal cancer in hereditary nonpolyposis colorectal cancer. Am J Surg: 2001; 181 3 207 210 (Pubitemid 32480216)
25. Jenkins MA. Role of MSH6 and PMS2 in the DNA mismatch repair process and carcinogenesis. Surg Oncol Clin N Am: 2009; 18 4 625 636
26. Hampel H, Frankel WL, Martin E., et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med: 2005; 352 18 1851 1860
27. Lynch PM. The hMSH2 and hMLH1 genes in hereditary nonpolyposis colorectal cancer. Surg Oncol Clin N Am: 2009; 18 4 611 624
28. Bao F, Panarelli NC, Rennert H, Sherr DL, Yantiss RK. Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma. Am J Surg Pathol: 2010; 34 12 1798 1804
29. Choi MY, Lauwers GY, Hur C, Willett CG, Chung DC. Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. Int J Radiat Oncol Biol Phys: 2007; 68 5 1584 (Pubitemid 47176835)
30. Ondrejka SL, Schaeffer DF, Jakubowski MA, Owen DA, Bronner MP. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing? Am J Surg Pathol: 2011; 35 9 1327 1330
31. Heijink DM, de Vries EG, Koornstra JJ., et al. Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome. Crit Rev Oncol Hematol: 2011; 80 2 264 277
32. Burn J, Bishop DT, Mecklin JP., et al. CAPP2 Investigators Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med: 2008; 359 24 2567 2578
33. Burn J, Gerdes AM, Macrae F., et al. CAPP2 Investigators Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet: 2011; 378 9809 2081 2087
34. Rijcken FE, Hollema H, van der Zee AG, van der Sluis T, Boersma-van Ek W, Kleibeuker JH. Sulindac treatment in hereditary non-polyposis colorectal cancer. Eur J Cancer: 2007; 43 8 1251 1256
35. López-Ramos C, Castells A. Chemoprevention in the Lynch syndrome: what can we do? Gastroenterology: 2009; 137 2 730 732
36. Cats A, Kleibeuker JH, van der Meer R., et al. Randomized, double-blinded, placebo-controlled intervention study with supplemental calcium in families with hereditary nonpolyposis colorectal cancer. J Natl Cancer Inst: 1995; 87 8 598 603
37. Kleibeuker JH, Cats A, van der Meer R, Lapré JA, de Vries EG. Calcium supplementation as prophylaxis against colon cancer? Dig Dis: 1994; 12 2 85 97
38. Strate LL, Syngal S. Hereditary colorectal cancer syndromes. Cancer Causes Control: 2005; 16 3 201 213 (Pubitemid 40903116)
39. Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med: 1998; 129 10 787 796 (Pubitemid 28522813)